Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment

被引：15
|
作者：
Yang, Fei-Fei [1 ,2 ,3 ,4 ]
Hu, Ting [1 ,2 ,3 ,4 ]
Liu, Jian-Quan [1 ,2 ,3 ,4 ]
Yu, Xiao-Qian [1 ,2 ,3 ,4 ]
Ma, Li-Ying [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450001, Henan, Peoples R China
[2] Zhengzhou Univ, Minist Educ China, Key Lab Adv Pharmaceut Technol, Zhengzhou 450001, Henan, Peoples R China
[3] Zhengzhou Univ, Inst Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[4] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[5] China Meheco Topfond Pharmaceut Co, Key Lab Cardio Cerebrovasc Drug, Zhumadian 463000, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 245卷
基金：
中国博士后科学基金;
关键词：
Hematologic cancer; HDACs; Immunotherapy; NKG2D LIGAND EXPRESSION; B-CELL LYMPHOMA; ACUTE MYELOID-LEUKEMIA; NON-HODGKIN-LYMPHOMA; REGULATORY T-CELLS; MULTIPLE-MYELOMA; ANTITUMOR IMMUNITY; VALPROIC ACID; TUMOR-CELLS; IN-VIVO;
D O I：
10.1016/j.ejmech.2022.114920
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Bone marrow transplantation is regarded as the most effective immunotherapy for hematologic cancer, but it generally faces difficulties in matching. Aberrant expression of histone deacetylases (HDACs) is closely related to the occurrence and development of hematological cancer. Recent studies suggested that HDACs might play a critical role in initiating anti-cancer immune response or enhancing anti-cancer immunotherapy. Besides, combining HDAC inhibition and immunotherapy could prevent immunotherapy resistance in some degree and reach an extended treatment window. This review summarized the relationship between HDACs and immune and described the current understanding of HDACs in immunotherapy for hematologic cancer.
引用
收藏
页数：13
相关论文
共 50 条
  • [31] Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer
    Xiang, Xue-Song
    Li, Peng-Cheng
    Wang, Wen-Quan
    Liu, Liang
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (01):
  • [32] Histone deacetylases as therapeutic targets - From cancer to cardiac disease
    Abend, Alon
    Kehat, Izhak
    PHARMACOLOGY & THERAPEUTICS, 2015, 147 : 55 - 62
  • [33] Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents
    Wahi, Abhishek
    Jain, Priti
    Sinhari, Apurba
    Jadhav, Hemant R.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (02) : 675 - 702
  • [34] Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents
    Abhishek Wahi
    Priti Jain
    Apurba Sinhari
    Hemant R. Jadhav
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397 : 675 - 702
  • [35] Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs)
    Linciano, Pasquale
    Benedetti, Rosaria
    Pinzi, Luca
    Russo, Fabiana
    Chianese, Ugo
    Sorbi, Claudia
    Altucci, Lucia
    Rastelli, Giulio
    Brasili, Livio
    Franchini, Silvia
    BIOORGANIC CHEMISTRY, 2021, 106
  • [36] Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs
    Hassig, CA
    Schreiber, SL
    CURRENT OPINION IN CHEMICAL BIOLOGY, 1997, 1 (03) : 300 - 308
  • [37] Histone Deacetylases as Targets for Multiple Diseases
    Sangshetti, Jaiprakash N.
    Sakle, Nikhil S.
    Dehghan, M. H. G.
    Shinde, Devanand B.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 1005 - 1026
  • [38] Histone deacetylases as targets for antitrypanosomal drugs
    Zuma, Aline A.
    de Souza, Wanderley
    FUTURE SCIENCE OA, 2018, 4 (08):
  • [39] Tumor-Infiltrating B Lymphocytes: Promising Immunotherapeutic Targets for Primary Liver Cancer Treatment
    Milardi, Giulia
    Lleo, Ana
    CANCERS, 2023, 15 (07)
  • [40] Histone deacetylases and cancer
    Barneda-Zahonero, Bruna
    Parra, Maribel
    MOLECULAR ONCOLOGY, 2012, 6 (06) : 579 - 589
12345